Subject: Relevance of Sitagliptin in Indian type 2 diabetes patients with Ease of administration & Durable Control
Diabetes mellitus has reached epidemic proportions and continues to be a major burden on society globally. The International Diabetes Federation (IDF) estimated the global burden of diabetes to be 366 million in 2011 and predicted that by 2030 this will have risen to 552 million. India accounts for 1 in 7 of all adults living with diabetes worldwide with prevalence of 74.2 million. Prevalence is expected to reach 125 million by 2045. In spite of newer and effective treatment options, newer delivery and diagnostic devices, stricter glycemic targets, better treatment guidelines and increased awareness of the disease, baseline glycosylated hemoglobin remains relatively high in subjects diagnosed and treated with type 2 diabetes. The search continues for an ideal anti diabetic drug that will not only normalize blood glucose but also provide beta cell rest and possibly restoration of beta cell function. The ideal therapeutic approach to treating type 2 diabetes is not yet determined. The present questionnaire is an attempt to find out the challenges in current treatment algorithm in diabetes management.
|
}}){kind=logo}
}})